NCT06526000

Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies

Retrospective EMR Study to Assess Changes in Immunoglobulins in Patients With Relapsing Forms of Multiple Sclerosis Treated With Anti-CD20 Monoclonal Antibodies

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 326 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This was an observational retrospective cohort study using electronic medical records (EMRs) to study immunoglobulin levels over time among patients with relapsing forms of multiple sclerosis (MS) newly initiating anti-CD20 monoclonal antibody treatment in clinical practice. The index date was defined as the date of anti-CD20 drug initiation during the study period. The baseline period was defined as 12 months prior to the index date.

Conditions

• Relapsing Multiple Sclerosis
• Clinically Isolated Syndrome
• Relapsing-remitting Multiple Sclerosis
• Secondary Progressive Multiple Sclerosis

Timeline

• Start date: 2022-10-11
• Primary completion: 2024-02-28
• Completion: 2024-02-28
• First posted: 2024-07-29
• Last updated: 2024-07-29

Locations

1 site across 1 country: United States